Ledyard National Bank Increases Holdings in Pfizer Inc. (NYSE:PFE)

Ledyard National Bank grew its holdings in Pfizer Inc. (NYSE:PFE) by 3.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 377,732 shares of the biopharmaceutical company’s stock after acquiring an additional 13,266 shares during the quarter. Pfizer comprises 1.1% of Ledyard National Bank’s investment portfolio, making the stock its 27th biggest holding. Ledyard National Bank’s holdings in Pfizer were worth $10,875,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the 3rd quarter valued at $30,000. GoalVest Advisory LLC grew its holdings in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer during the third quarter worth about $34,000. VisionPoint Advisory Group LLC lifted its holdings in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the company. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $36.33.

Pfizer Price Performance

Shares of PFE traded up $0.25 during trading hours on Monday, reaching $25.65. The company had a trading volume of 41,630,566 shares, compared to its average volume of 41,999,020. The company has a market capitalization of $145.24 billion, a price-to-earnings ratio of 71.25, a PEG ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The firm has a 50 day simple moving average of $26.92 and a 200-day simple moving average of $28.31. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period last year, the firm earned $1.14 EPS. Research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.55%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is currently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.